Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial.

Day TA, Shirai K, O'Brien PE, Matheus MG, Godwin K, Sood AJ, Kompelli A, Vick JA, Martin D, Vitale-Cross L, Callejas-Varela JL, Wang Z, Wu X, Harismendy O, Molinolo AA, Lippman SM, Van Waes C, Szabo E, Gutkind JS.

Clin Cancer Res. 2019 Feb 15;25(4):1156-1164. doi: 10.1158/1078-0432.CCR-18-2024. Epub 2018 Nov 12.

PMID:
30420444
2.

A retroinhibition approach reveals a tumor cell-autonomous response to rapamycin in head and neck cancer.

Amornphimoltham P, Patel V, Leelahavanichkul K, Abraham RT, Gutkind JS.

Cancer Res. 2008 Feb 15;68(4):1144-53. doi: 10.1158/0008-5472.CAN-07-1756.

3.

Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.

Amornphimoltham P, Patel V, Sodhi A, Nikitakis NG, Sauk JJ, Sausville EA, Molinolo AA, Gutkind JS.

Cancer Res. 2005 Nov 1;65(21):9953-61.

4.

Teasing out the best molecular marker in the AKT/mTOR pathway in head and neck squamous cell cancer patients.

Clark C, Shah S, Herman-Ferdinandez L, Ekshyyan O, Abreo F, Rong X, McLarty J, Lurie A, Milligan EJ, Nathan CO.

Laryngoscope. 2010 Jun;120(6):1159-65. doi: 10.1002/lary.20917.

5.

Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model.

Sun ZJ, Zhang L, Hall B, Bian Y, Gutkind JS, Kulkarni AB.

Clin Cancer Res. 2012 Oct 1;18(19):5304-13. doi: 10.1158/1078-0432.CCR-12-1371. Epub 2012 Aug 2.

6.

Significance of mammalian target of rapamycin in patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil.

Li SH, Lin WC, Huang TL, Chen CH, Chiu TJ, Fang FM, Huang WT, Hsu CM, Luo SD, Lai CC, Su YY, Chuang HC, Chien CY.

Head Neck. 2016 Apr;38 Suppl 1:E844-52. doi: 10.1002/hed.24111. Epub 2015 Jul 18.

PMID:
25917382
7.

PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.

Herzog A, Bian Y, Vander Broek R, Hall B, Coupar J, Cheng H, Sowers AL, Cook JD, Mitchell JB, Chen Z, Kulkarni AB, Van Waes C.

Clin Cancer Res. 2013 Jul 15;19(14):3808-19. doi: 10.1158/1078-0432.CCR-12-2716. Epub 2013 May 2.

9.

Morphoproteomic and pharmacoproteomic rationale for mTOR effectors as therapeutic targets in head and neck squamous cell carcinoma.

Brown RE, Zhang PL, Lun M, Zhu S, Pellitteri PK, Riefkohl W, Law A, Wood GC, Kennedy TL.

Ann Clin Lab Sci. 2006 Summer;36(3):273-82. Erratum in: Ann Clin Lab Sci. 2006 Autumn;36(4):442. Riefkohl, Waldemar [added].

PMID:
16951268
10.

mTOR, metabolism, and the immune response in HPV-positive head and neck squamous cell cancer.

Coppock JD, Lee JH.

World J Otorhinolaryngol Head Neck Surg. 2016 Jul 20;2(2):76-83. doi: 10.1016/j.wjorl.2016.05.010. eCollection 2016 Jun. Review.

11.

mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas.

Molinolo AA, Marsh C, El Dinali M, Gangane N, Jennison K, Hewitt S, Patel V, Seiwert TY, Gutkind JS.

Clin Cancer Res. 2012 May 1;18(9):2558-68. doi: 10.1158/1078-0432.CCR-11-2824. Epub 2012 Mar 12.

12.

Inhibition of rapamycin-induced AKT activation elicits differential antitumor response in head and neck cancers.

Radhakrishnan P, Baraneedharan U, Veluchamy S, Dhandapani M, Pinto DD, Thiyagarajan S, Thayakumar A, Prasath A, A K, Velu A, Jain M, Brijwani N, Narayanan P, Kekatpure VD, Majumder B, Majumder PK.

Cancer Res. 2013 Feb 1;73(3):1118-27. doi: 10.1158/0008-5472.CAN-12-2545. Epub 2013 Jan 29.

13.

Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies.

Javle MM, Shroff RT, Xiong H, Varadhachary GA, Fogelman D, Reddy SA, Davis D, Zhang Y, Wolff RA, Abbruzzese JL.

BMC Cancer. 2010 Jul 14;10:368. doi: 10.1186/1471-2407-10-368.

14.

The Expression and Prognostic Impact of the PI3K/AKT/mTOR Signaling Pathway in Advanced Esophageal Squamous Cell Carcinoma.

Wu N, Du Z, Zhu Y, Song Y, Pang L, Chen Z.

Technol Cancer Res Treat. 2018 Jan 1;17:1533033818758772. doi: 10.1177/1533033818758772.

15.

Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma.

Massarelli E, Lin H, Ginsberg LE, Tran HT, Lee JJ, Canales JR, Williams MD, Blumenschein GR Jr, Lu C, Heymach JV, Kies MS, Papadimitrakopoulou V.

Ann Oncol. 2015 Jul;26(7):1476-80. doi: 10.1093/annonc/mdv194. Epub 2015 May 29.

16.

Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative.

Molinolo AA, Hewitt SM, Amornphimoltham P, Keelawat S, Rangdaeng S, Meneses GarcĂ­a A, Raimondi AR, Jufe R, Itoiz M, Gao Y, Saranath D, Kaleebi GS, Yoo GH, Leak L, Myers EM, Shintani S, Wong D, Massey HD, Yeudall WA, Lonardo F, Ensley J, Gutkind JS.

Clin Cancer Res. 2007 Sep 1;13(17):4964-73.

17.

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma.

Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent J, Horvath S, Mischel PS, Mellinghoff IK, Sawyers CL.

PLoS Med. 2008 Jan 22;5(1):e8. doi: 10.1371/journal.pmed.0050008.

18.

mTOR inhibition as an adjuvant therapy in a metastatic model of HPV+ HNSCC.

Coppock JD, Vermeer PD, Vermeer DW, Lee KM, Miskimins WK, Spanos WC, Lee JH.

Oncotarget. 2016 Apr 26;7(17):24228-41. doi: 10.18632/oncotarget.8286.

19.

Targeting mammalian target of rapamycin by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model.

Czerninski R, Amornphimoltham P, Patel V, Molinolo AA, Gutkind JS.

Cancer Prev Res (Phila). 2009 Jan;2(1):27-36. doi: 10.1158/1940-6207.CAPR-08-0147.

20.

A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma.

Teknos TN, Grecula J, Agrawal A, Old MO, Ozer E, Carrau R, Kang S, Rocco J, Blakaj D, Diavolitsis V, Kumar B, Kumar P, Pan Q, Palettas M, Wei L, Baiocchi R, Savvides P.

Invest New Drugs. 2018 Dec 19. doi: 10.1007/s10637-018-0696-4. [Epub ahead of print]

PMID:
30569244

Supplemental Content

Support Center